Adult Sinusitis Guidelines Updated

From NEJM Journal Watch - April 2015
By Kelly Young
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM

The American Academy of Otolaryngology—Head and Neck Surgery Foundation has updated its 2007 guidelines on managing adult sinusitis.
The guidelines, published in Otolaryngology—Head and Neck Surgery, stress shared decision-making between clinicians and patients, particularly in determining whether to try watchful waiting for uncomplicated acute bacterial sinusitis or to prescribe antibiotics right away.
Some of the other changes in recommendations include:
  • To relieve the symptoms of acute bacterial rhinosinusitis, clinicians may recommend analgesics, topical intranasal steroids, nasal saline irrigation, or a combination.
  • When antibiotics are prescribed, the recommended first-line treatment is amoxicillin with or without clavulanate for 5–10 days.
  • For chronic rhinosinusitis, clinicians should assess the patient for other chronic conditions (e.g., asthma) that would modify treatment; should check for nasal polyps; may test allergy and immune function; and should not prescribe topical or systemic antifungal treatment. 
Link(s):



Comments

Popular posts from this blog

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss: What the Evidence Shows

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity

9 Best Berberine Supplements (2026 Review): Evidence, Dosage & New EU Safety Data

Bryan Johnson's Supplements List: Insider's Guide (2026 Update)

Best Injectable Peptides for Anti Aging 2026

NAC vs NAD vs NR vs NMN vs Niacin: What Are the Differences?

The Science Behind Stem Cell Therapy: Research Review and Future Prospects (2026)